Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 231

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators

Open access
Piccinin, Elena, Villani, Gaetano, Moschetta, Antonio · 2019 · Nature Reviews Gastroenterology & Hepatology

Abstract

Alterations of hepatic metabolism are critical to the development of liver disease. The peroxisome proliferator-activated receptor-γ coactivators (PGC1s) are able to orchestrate, on a transcriptional level, different aspects of liver metabolism, such as mitochondrial oxidative phosphorylation, gluconeogenesis and fatty acid synthesis. As modifications affecting both mitochondrial and lipid metabolism contribute to the initiation and/or progression of liver steatosis, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), a link between disrupted PGC1 pathways and onset of these pathological conditions has been postulated. However, despite the large quantity of studies, the scenario is still not completely understood, and some issues remain controversial. Here, we discuss the roles of PGC1s in healthy liver and explore their contribution to the pathogenesis and future therapy of NASH and HCC.The liver is a key metabolic organ, and alterations to hepatic metabolism are important for the development of disease. In this Review, the authors explore the central roles of peroxisome proliferator-activated receptor-γ coactivators (PGC1s) in physiological and pathophysiological settings, with a focus on nonalcoholic fatty liver disease and liver cancer.Key pointsPeroxisome proliferator-activated receptor-γ coactivators (PGC1s) have a key role in liver metabolism and contribute to energy homeostasis.PGC1α and PGC1β exert divergent functions on liver metabolism and regulate different pathways.Although the hepatic expression of both PGC1α and PGC1β negatively correlates with nonalcoholic fatty liver disease (NAFLD) severity, hepatocellular carcinoma (HCC) development is inhibited by PGC1α and promoted by PGC1β.Although direct coactivator targeting is problematic, pharmacological modulation of transcriptional and post-transcriptional activators of PGC1s is an appealing therapeutic avenue.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41575-018-0089-3

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 231

Metadata

Authors
Piccinin, E., Villani, G., & Moschetta, A.
Venue
Nature Reviews Gastroenterology & Hepatology
Published
2018-12-05
Volume
16
Issue
3
Pages
160-174
ISSN
  • 1759-5045 (ISSN-L)
  • 1759-5053
OpenAlex
W2902086897
Cited by
231
References
55
FWCI
4.08
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators. https://app.cochat.ai/papers/10.1038/s41575-018-0089-3
The paper
Piccinin, E., Villani, G., & Moschetta, A. (2019). Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-018-0089-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.